At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Tedizolid PO +1 moredrug
Likely dose
Tedizolid PO 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Steady-State Pharmacokinetics of Tedizolid in Plasma and Sputum of Patients With Cystic Fibrosis
In Brief
A Phase 4 clinical trial evaluating Tedizolid PO and Tedizolid IV for Cystic Fibrosis. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionDec 2017
TodayJul 2026
First PostedMay 14, 2015
Enrollment StartJul 1, 2015
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.1 years ago
Interventions
Tedizolid POdrug
Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
Tedizolid IVdrug
Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.